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Abstract: Since 1992, the maternal–fetal route of transmission has become the dominant 
route for acquisition of hepatitis C (HCV) infection by children. With increasing knowledge 
of antiviral treatment for HCV infection, the main goal of therapy is to achieve a sustained 
virological response (SVR) as defined by undetectable serum HCV RNA by polymerase chain 
reaction assay six months after cessation of therapy. In young children, interferon therapy is 
more effective than in adults with chronic HCV infection (CHC). Although children clearly 
have a milder degree of liver pathology, data have indicated that hepatic inflammation from 
HCV infection can progress to fibrosis or cirrhosis in children. Hepatocellular carcinoma has 
been reported in adolescents with CHC. In this article, recent improvements in therapy of 
children with CHC and in the clinical development of new emerging drugs with potential use 
in children will be reviewed.
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Introduction
Hepatitis C virus (HCV) was first discovered in 1989 and ever since, HCV infection 
has become a global public health problem. The prevalence of HCV varies in 
different parts of the world.1,2 It is estimated that 170 million people worldwide have 
been or are infected with HCV. There are approximately seven million adults and 
100,000 children infected with chronic HCV (CHC) in the United States.3 Although 
transfusion-transmitted HCV was the major form of HCV in the pediatric age group 
when the virus was first described,4,5 since 1992, when the majority of blood units 
transfused have been free of HCV (estimated to be 0.01%–0.001% per transfusion,4–6 
the maternal–fetal route of transmission of this virus has become the dominant route 
for new cases of HCV.
The main goal of therapy in HCV infection is to achieve a sustained virologic 
response (SVR; Table 1). Late relapse is rare after SVR. Virologic data indicate the 
durability of undetectable virus from serum in almost all cases (99%) after SVR.7 This 
goal is practically equivalent with eradication of HCV infection and cure of the under-
lying HCV-induced liver disease.8 Since 2005, the current standard in HCV treatment 
in adults consists of combination regimens of pegylated interferon-α (pegIFN-α) with 
ribavirin (RBV). However, this treatment is associated with several and sometimes 
severe adverse effects, limiting the efficacy and applicability in an appreciable number 
of patients with CHC-induced liver disease.9 The treatment is relatively contraindicated 
in end-stage liver and renal disease. Therefore, the need for improvement of existing Therapeutics and Clinical Risk Management 2009:5 652
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therapies and for development of new effective, safe, and 
tolerable drugs is a matter of great clinical relevance and 
importance. Although there are a number of potentially new 
drugs currently being tested in adults which appear to more 
effective than the current therapy, these will need careful 
study in the pediatric population before general use.
Development in HCV therapy and 
ongoing clinical drug trials in adults
In several clinical trials, the response to treatment can be 
categorized as biochemical, virologic, or histologic. Quantita-
tive assessment of paired liver biopsy pre- and post-treatment 
has been standardized.8 As the efficacy of HCV treatment 
has improved, terminology for virologic response is com-
monly used in predicting and comparing the outcome of 
HCV treatment (Table 1).10
Type 1 IFNs are natural cellular proteins with variable 
actions such as inhibition of HCV replication, induction of 
cytokine secretion, recruitment of immune effector cells, 
and induction of cell differentiation. IFN was the only 
treatment option until the mid-1990s. IFN-based treatments 
were different types and regimen but in general resulted in 
15%–20% SVR.11 RBV is a purine nucleoside analogue that 
works by inhibiting host enzyme inosine monophosphate 
dehydrogenase (IMPDH) and HCV polymerase, thereby 
inhibiting replication of the viral genome, RNA virus 
mutagenesis, and improving T-cell functions and response to 
HCV infection.12 RBV was approved to be used in combina-
tion therapy since 1998 as RBV monotherapy did not result 
in impressive SVR.13 Combination therapy with IFN and 
RBV augmented the SVR to 35%–40% and by late 1998, 
randomized placebo-controlled trials in the therapy proved of 
superior efficacy in treatment-naïve CHC patients with 24 or 
48 weeks of combination therapy, with an SVR of 31% and 
43%, respectively compared to IFN monotherapy with a SVR 
of 18%.14–16 Improved SVR with combination therapy was 
also observed in those with advanced fibrosis and cirrhosis 
who failed IFN monotherapy.17 SVR increased from 29% to 
38% when combination therapy was prolonged from 24 to 
48 weeks, respectively. Hepatocellular carcinoma (HCC) 
markedly decreased among those with an SVR.18,19 Favorable 
parameters for combination therapy are similar to that for 
IFN monotherapy including genotype 2 and 3, low viral load 
with serum HCV-RNA  2 million copies/mL, age less than 
40 years, minimal fibrosis on biopsy and female gender.20
PegIFN is a recombinant IFN-α either 2a or 2b, covalently 
bound to polyethylene glycol (PEG) to standard IFN and 
does not alter the pharmacodynamics or safety/tolerability 
profiles of IFN-α.21 It reduces the difference between serum 
peaks and troughs and prolongs its half-life. PEG molecule in 
PegIFN-α 2a is a branched 40-kD molecule with elimination 
half-life of 80 hours, while that in PegIFN-α 2b is a linear 
12-kD molecule with elimination half-life of 40 hours. No 
significant differences were noted between the two pegIFN 
molecules plus RBV in terms of SVR.22 PegIFN/RBV is 
the mainstay of HCV therapy and patients with genotype 1 
infection receiving a combination therapy of pegIFN/RBV 
have the SVR rate of 40% to 55% vs 70% to 90% among 
those with genotype 2 or 3 infection.23 Long-term ben-
efits include decreased morbidity and mortality, including 
decreased rates of HCC and improved quality of life for the 
patients and family.24 More data from randomized control 
trials indicated that some genotype 2 and 3 patients are 
undertreated, with one guideline recommending the therapy 
Table 1 Terminology for virologic response commonly used in predicting the outcome of hepatitis C virus (HCv) treatment10
Terminology Definition
Sustained virologic response (SvR) Undetectable serum HCv-RNA determined with the most sensitive polymerase 
chain reaction (PCR) technique 24 weeks after the end of treatment (eTR)
Rapid virologic response (RvR) Undetectable serum HCv RNA (50 iU/ml) by treatment week 4
early virologic response (evR) 2 log10 iU/mL (100-fold) decline in serum HCv RNA from pretreatment baseline 
or undetectable serum HCv RNA by treatment week 12
Partial virologic response 2 log10 iU/mL (100-fold) decline in serum HCv RNA from pretreatment baseline 
at treatment week 12 but serum HCv RNA still detectable at treatment week 24
Null response 2 log10 iU/mL (100-fold) decline in serum lf HCv RNA from pretreatment 
baseline 12 weeks after treatment was initiated
virologic breakthrough Reappearance of serum HCv RNA during treatment after initially becoming 
undetectable HCv RNA
Relapse Reappearance of serum HCv RNA after the treatment were discontinued in a 
patient who achieved and maintained undetectable HCv RNA throughout the 
duration of treatmentTherapeutics and Clinical Risk Management 2009:5 653
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for 24 weeks in patients with these genotypes.20 Patients with 
genotype 1 or 4 require 48 weeks of treatment.20 In future, 
treatment guidelines will require further studies evaluating 
other independent viral and host factors which affect the 
predictive value of early virologic response (EVR) and rapid 
virologic response (RVR).7
Patients with CHC who fail to respond to initial therapy 
with pegIFN and RBV are still at risk for developing 
progression of their liver disease, but retreatment with 
pegIFN/RBV yields low SVR rates (10%).6 Long-term IFN 
has been considered for patients who failed previous anti-
viral therapies.25 Albuferon (albumin-interferon alpha 2b), 
a recombinant single polypeptide molecule coded by the 
fusion of the human serum albumin and the IFN-α genes, 
can be dosed once every two weeks or even once every four 
weeks.26 A wholly synthetic IFN alfacon-1 or consensus 
IFN (CIFN),27–29 a recombinant type 1 IFN derived by scan-
ning the sequences of several natural alpha IFNs, displays 
5–10 times higher biological activity than conventional IFN. 
However, it appears unlikely that Albuferon or CIFN will 
replace pegIFN and RBV, unless a clear advantage over 
them in effectiveness or side effects is demonstrated in the 
ongoing or future studies.6,30
Specifically targeted antiviral therapy for HCV has been 
developed based on the molecular structure of HCV, its 
component proteins, and the various phases of the replication 
cycle of the virus. HCV antiviral development involves all 
three of classes, HCV protease inhibitors (PIs), nucleoside 
HCV polymerase inhibitors (NIs), and nonnucleoside HCV 
polymerase inhibitors (NNIs). Only two direct-acting HCV 
inhibitors entered phase III trials in 2008, both of which 
are PIs (telaprevir and boceprevir).31 The success of HIV 
antiviral therapy gave hope that HCV NS3-4A protease 
could be an excellent target for a structural-base design 
approach. When telaprevir was added to baseline regimens of 
pegIFN-α2a in group 1 (telaprevir with pegIFN-α2a/RBV for 
12 weeks followed by pegIFN-α2a/RBV alone for 12 weeks) 
and compared to group 2 (telaprevir with pegIFN-α2a/
RBV for 12 weeks), the antiviral efficacy improved over 
group 3 (telaprevir with pegIFN-α2a for 12 weeks) or group 4 
(pegIFN-α2a alone for 48 weeks) with SVRs of 69%, 60%, 
36%, and 46%, respectively.32 This result suggests that RBV is 
important for improving SVR with telaprevir/pegIFN treatment. 
The HCV-RNA-dependent RNA polymerase (HCV Pol) can 
be inhibited either by nucleoside/nucleotide analogues or by 
nonnucleoside analogue molecules. The NS5b-encoded HCV 
Pol is an RNA-dependent RNA polymerase that has two types 
of binding sites available for inhibitors of HCV Pol inhibitors. 
NIs bind in the HCV Pol catalytic (active) site and NNIs can 
bind four (or more) other sites on HCV Pol located outside the 
active site.31 Currently several agents are under development 
on phase I and II trials, whereas some were withdrawn because 
of safety concerns.20
Taribavirin hydrochloride, a liver-targeting prodrug for 
RBV, preferentially releases RBV at the level of the hepa-
tocyte and does not significantly accumulate in erythrocytes. 
However it has not achieved comparable rates of efficacy 
with less hemolysis.33 Antisense oligonucleotide molecules, 
ribozymes, or small interfering RNAs (siRNAs) can interrupt 
the internal ribosome entry site (IRES) region of HCV RNA 
binding of the 40S ribosomal subunit and result in conforma-
tional changes in the ribosome disrupting the viral life-cycle 
of the virus by cleaving the RNA genome.20,34 The develop-
ment of some of these agents is still in an early phase, limited 
to laboratory cell lines. The development of others has been 
interrupted because of adverse effects and limited efficacy.34
Among the most promising therapeutic agents in devel-
opment are the agonists of the Toll-like receptors (TLR). 
TLR are pathogen recognition molecules expressed on 
immunologic cells that sense the presence of invading 
microorganisms and initiate the innate immune response 
or acute inflammation. Stimulation of the appropriate TLR 
may induce and restore a potent innate and adaptive immune 
response which is usually dysfunctional in patients with 
CHC.20,35 To date, drugs that have an agonistic action with 
the TLR9 (CPG 10101 or Actilon) and TLR7 (ANA245 or 
Isatoribine) mimicking their function are under development 
for therapy of HCV infection.20,35
Increased rates of hepatocyte apoptosis and activated 
caspases have been observed in CHC.36 Antifibrotic agents 
such as angiotensin receptor blockers and drugs regulating 
apoptosis pathways have been used in patients with CHC with 
compensated cirrhosis.37 Inhibiting caspases with a specific 
pancaspase inhibitor may play an important role in HCV 
treatment and cirrhosis in the future. IDN-6556, a potent inhibi-
tor of caspases, the proteases that execute apoptosis lowered 
serum aminotransferase activity in a small number of patients 
with liver impairment in a prior phase I study, yet requires 
longer duration studies.38 When patients decompensate, ortho-
topic liver transplantation (OLT) is considered. The outcome 
of OLT in adults with CHC has been suboptimal and is limited 
by almost universal recurrent infection.39
Current pediatric data
The estimated prevalence of HCV antibody in children 
and adolescents aged up to 14 years was 0.2% to 0.4% in Therapeutics and Clinical Risk Management 2009:5 654
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the National Health and Nutrition Examination Survey III 
population-based survey with approximately 100,000 children 
infected with CHC in the United States.3,40 The prevalence 
of anti-HCV antibody in pregnant women is 0.1%–2.4%. 
Transmission rates are 4%–7% when the mother is viremic 
and mothers with HCV RNA  106 copies per mL are more 
likely to transmit the infection to the fetus compared to 
mothers with lower levels of viremia.41 Co-infection with 
the HIV virus increases the risk of transmission 4–5-fold but 
highly active retroviral therapy may significantly decrease 
this risk.42 The rate of viral clearance rates in children with 
CHC was 8% in a large prospective 10 year study; most of 
the children who cleared HCV did so in the first five years 
of follow-up.43,44 The significance of HCV RNA levels in 
long-term clinical outcomes of children with CHC is not 
well understood. A long-term follow-up study of 42 children 
with CHC demonstrated that children with an HCV RNA 
level below 4.5 × 10(4) IU/mL at enrollment have a higher 
spontaneous viral clearance rate.44
Although the natural course of CHC in children is 
thought to be insidious over more than 10–15 years,45,46 
121 treatment-naïve children in the PEDS-C trial demonstrated 
the presence of inflammation, fibrosis, and steatosis in liver 
biopsies taken at the beginning of the trial.40 However the 
degree of abnormality was milder than that reported for 
treatment-naïve adults with CHC. The positive correlation of 
inflammation with duration of infection and fibrosis and of 
obesity with fibrosis suggest that children with CHC will be 
at risk for progressive liver disease as they age and possibly 
acquire other comorbid risk factors.40 Since the majority of 
children with CHC contracted HCV via maternal-to-fetal 
acquisition, they may develop chronic liver disease and 
its complication in the second or third decade.47 HCC was 
reported in two young adolescents with CHC.3 Although 
Rodrigue and colleagues found that children with HCV 
infection in in the PEDS-C trial did not have global impair-
ment in cognitive, behavioral, and emotional function at entry 
into the study, the authors did find higher caregiver stress and 
strain on the family system.48 All these factors along with 
the safety and efficacy of medications should play a role in 
decision-making for the therapy in children with CHC.
The European Paediatric Hepatitis C Virus Network 
reported the natural history of 266 children with vertical 
HCV infection; approximately 20% appeared to clear the 
infection, 50% had evidence of chronic asymptomatic 
infection, and 30% had evidence of chronic active infection.49 
Children with transfusion-acquired HCV also tend to have 
mild asymptomatic infection although rarely may proceed 
to decompensated liver disease and liver transplantation.50 
In another large pediatric natural history study, 1.8% of 
children progressed to decompensated cirrhosis (mean age 
9.6 years). These children were mostly perinatally infected 
with genotype 1a and most of the mothers were intravenous 
drug users.43
Diagnosis is usually made by screening of high-risk children 
for anti-HCV antibody. Infection is confirmed by HCV RNA 
by polymerase chain reaction (PCR) assay. The American 
Academy of Pediatrics recommends that infants born to 
HCV-infected mothers be screened by anti-HCV at 18 months 
post-partum, since passively acquired maternal antibody can 
persist for up to 18 months.51 In clinical practice, children with 
positive anti-HCV could potentially be lost to follow-up before 
18 months as a result of social and compliance issues. For this 
reason, the PCR assays for HCV RNA could be helpful for early 
identification of these infants with HCV infection and provide 
adequate follow-up and proper education to the family.
Although in early 2000 no therapeutic regimen had 
received United States Food and Drug Administration (FDA) 
approval for treating children with CHC, there have been 
already a number of pediatric IFN-α trials and 20 published 
manuscripts of the use of IFN monotherapy in children with 
CHC. Of the 19 trials, 366 treated and 105 untreated children 
were observed; five countries were represented.52 Average 
ETR was 54% (0%–91%) and the average SVR was 36% 
(0%–73%). The SVR in children with genotype 1 was 27% vs 
70% for nongenotype 1. Five of 105 (5%) untreated controls 
exhibited spontaneous viral clearance. Therefore IFN-α 
monotherapy was not generally recommended in children with 
CHC genotype 1 given the poor result. IFN-α 2b at a dose of 
3 or 5 MU/m2 three times weekly in combination with oral 
RBV (15 mg/kg/d) for 12 months proved to be effective in the 
treatment of CHC in children and adolescents for both verti-
cally infected patients and for individuals with pre-treatment 
normal or elevated serum aminotransferase levels. The SVR 
was 61%.53 The improved disease outcome and compliance to 
therapy with weekly pegIFN in adult HCV patients and small 
pilot studies in children with CHC suggested that the therapy 
may also improve antiviral efficacy in children. The ideal trial 
would be large scale, prospective, and controlled, and would 
include HCV genotype and viral load, histology, quality of 
life measures, and systematic recording of adverse events and 
of effects of therapy on growth and development.
The pharmacokinetics, efficacy and safety of pegylated 
interferon alpha2a (pegIFN-α2a) (40 kd) were first investi-
gated in 14 children aged 2 to 8 years with CHC (13 genotype 1, 
1 non-1 genotype).54 The drug dose was calculated from each Therapeutics and Clinical Risk Management 2009:5 655
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patient’s body surface area (BSA) according to the formula 
BSA (m2)/(1.73 m2) × 180 µg, and patients were administered 
once-weekly subcutaneous injections for 48 weeks. At week 24, 
the mean trough concentration was about 20% below values 
obtained from adults treated with pegIFN-alpha2a, but the area 
under the curve from 0 to 168 hours was about 20% above 
adult values, suggesting that drug doses calculated from BSA 
achieved therapeutically adequate concentrations. All infected 
with genotype 1 achieved an SVR of 46% and the patients 
seemed to tolerate pegIFN well.54
A combination treatment of weekly pegIFN α-2b at a 
dose of 1.5 µg/kg body weight with RBV (15 mg/kg/day) 
for 48 weeks showed encouraging results in an open-labeled, 
uncontrolled pilot study with 62 children and adolescents 
(age 2–17 years). SVR was documented in 22 (48%) of 
46 patients with genotype 1, in 13 (100%) of 13 with genotype 
2 or 3, in one of two with genotype 4, in 19 (70%) of 27 
children.55 Although Baker and colleagues reported a small 
study (10 children, age 11–18 years) evaluating the safety 
and efficacy of pegIFN α-2b and RBV combination therapy 
for chronic HCV infection in the pediatric age group with a 
lower SVR of 30%, the study included children with both 
treatment-naïve patients and those who failed to respond to a 
previous course of antiviral therapy.56 The rationale for adding 
RBV to pegIFNα-2a therapy is the higher SVR in adult stud-
ies using this combination.57 The recommended RBV doses 
and the duration of treatment depend on HCV genotypes and 
baseline viral loads, and can be further individualized on the 
basis of RVR and EVR. PegIFN α-2a as monotherapy vs 
in combination with RBV in pediatric patients with CHC 
was the basis of the PEDS C trial, the first multicenter 
placebo-controlled trial for the treatment of CHC in children 
aged 5 years through 18 years.58 By 2008, there were two 
FDA-approved antiviral therapies for children: thrice weekly 
IFN plus RBV, indicated for children aged 3–18 years with 
HCV infection and once weekly pegIFN α-2b plus RBV 
for children aged 5–18 years; both are given 48 weeks for 
children with genotype 1 and 4. Children with genotype 2 or 
3 may require only 24 weeks of therapy like adults but the 
issue has not been well studied in children.58
Adverse effects in HCV therapy 
in children and their management
Although adverse effects and laboratory abnormalities 
related to treatments with standard IFN or pegIFN are 
similar including minor clinical signs such as fever, flu-like 
symptoms, headache, anorexia, neutropenia and more severe 
signs (21.4%) such as depression (less common in children), 
irritability, alopecia, and the development of thyroid and 
liver autoantibodies and impairment of thyroid function, the 
weekly administration of pegIFN minimizes fever, anorexia, 
or flu-like symptoms.55,59,60 Severe neurotoxicity in the form 
of spastic diplegia has been sporadically reported in infants 
using IFNα. This is so undesirable that that form of IFNα 
therapy has been avoided in infants younger than 1 year. 
In a recent study, five infants with hemangiomas developed 
a spastic diplegia during IFN-a therapy. The mechanisms of 
the neurotoxicity of IFN-a are not clear and spasticity appears 
late during the course of treatment, the cumulative dose and 
not the maximum daily dose may be an important factor. 
Interferon alpha-2a therapy in hemangiomas of infancy: 
spastic diplegia as a severe complication.61
The use of epoetin alfa and granulocyte colony-stimulating 
factor generally is not recommended or required for treating 
neutropenia and anemia, adverse effects from pegINF/RBV. 
Since these side effects are dose-dependent, dose reduction by 
20% to 30% of pegIFN has been performed based on degrees 
of neutropenia in a pediatric study.55
Common side effects of RBV include nausea, skin rash, 
cough, and shortness of breath. The most common side 
effect is hemolytic anemia which is dose-dependent and 
occurs during the first four weeks of therapy.62 Although 
dose-dependent hemolytic anemia was observed, it did not 
require drug discontinuation in any of 61 treated children.63 
The average decrease in hemoglobin is of 2 to 3 g. The 
degree of anemia also determines the adjustment of RBV 
dosage during the course of treatment; however the dose 
reduction may affect the SVR. In addition to hemolytic 
anemia, RBV has teratogenic and embryotoxic effects in 
animal studies and should be a major concern when using 
it in individuals of child-bearing age including both female 
and male adolescents.64 The long-term side effects of RBV 
in children and adolescents are still unknown. Therefore 
educating parents and patients about the natural disease, 
the treatment course of HCV infection, adverse effects of 
the treatment is essential at each visit.
Patient/family education 
and laboratory monitoring
Teaching sessions can be performed to parents at the time 
the patients receiving their first doses with premedication 
regimen (acetaminophen and diphenhydramine) in the 
clinic including selecting and rotating injection sites, site 
preparation, delivering medications, time of administration 
(at bedtime), sharp disposal, and storage of medications. 
Sex education, nutritional assessment, and psychiatric Therapeutics and Clinical Risk Management 2009:5 656
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screening should be addressed before the treatment and 
reinforced on follow-up visits.
There are specific advice following manufacturer 
guidelines on laboratory monitoring and dose adjustment 
for pegIFN and RBV. In general complete blood count, 
liver function test, thyroid function tests and also quantita-
tive RT-PCR of HCV RNA should be monitored at four 
weeks, 12 weeks, six months (genotype 2 and 3) or one year 
(genotype 1 and 4) and six months after the end of therapy.
New antiviral agents for pediatric use
In developing newer or more effective therapies, care-
ful attention should be paid to the unique physiology and 
psychological needs in pediatric population. Children 
generally have much lower viral loads and precirrhotic. 
The time elapsed from infection and diagnosis is shorter 
in most cases. Younger children also have been reported 
to clear the virus after acute HCV infection at a higher rate 
than older children and adults.63 At the same time caregiv-
ers with CHC are known to have great concern about their 
children’s health condition and often seek many opinions 
for HCV therapy.48
The PEDS-C trial is an example of great effort from 
devoted and interested pediatric subspecialists who studied 
pharmacokinetics and efficacy of the potential medications, 
developed a safe protocol for HCV therapy in pediatric 
populations in 2000–2008 and concluded annual follow-ups 
and all ancillary studies in 2009. The trial was financially 
supported by both government and Industry and included a 
highly functional organization of pediatric subspecialists, 
research coordinators, and investigational pharmacists, work-
ing together with government and industry scientists.58
Safety assessments are required prior to using new 
agents in children. Currently there have been no pediatric 
trials of PIs, Nis, NNIs, TLR agonists, thymosin, histamine, 
antifibrotic agents alone or in combination with (peg)IFN 
and RBV therapy. The future use of these agents in children 
with CHC is probably in combination with pegIFN and RBV; 
attempts should be made to minimize pegIFN side effects, 
perhaps by shortening the duration of therapy and to improve 
the SVR in all patients as well as to treat nonresponders 
or cirrhotic patients. Among these new agents, telaprevir 
seems the most promising in a clinical trial in patients (age 
range 18–65 years) with pegIFN and RBV.32 However drug-
induced rash occurred with the median time at 73 days (range 
8–88 days) after the start of treatment and severe rash and 
pruritus were a common indication to discontinue telaprevir 
in 12 of 175 patients with all telaprevir-based regimens.65 
Severe rash occurred in approximately 5% of patients treated 
with telaprevir.32 A good design for a pediatric trial might be 
a lead-in 60-day-period of telaprevir or placebo plus pegIFN/
RBV. As increased adverse effects with rash or anemia 
occur over the time of treatment (median time at 73 days), 
telaprevir would be likely tolerated in the first 60 days after 
the administration of this medication. Telaprevir could then 
be discontinued in those who do not respond or achieve 
viral response 2 log10 IU/mL decline in HCV RNA from 
pretreatment baseline at 60 days of the treatment to avoid 
these side effects.
Co-infection with HBV  
or HIV infection
HCV increases mortality in hepatitis B virus- (HBV) or 
human immunodeficiency virus- (HIV) infected patients 
as they develop accelerated liver disease and consequently 
cirrhosis, liver failure, and hepatocellular carcinoma.66 Treat-
ment for HCV infection in HIV-infected individuals includes 
with standard pegIFN/RBV or maintenance therapy with 
low-dose pegIFN, administered in an attempt to slow fibrosis 
progression.67 Response rates to HCV therapy are generally 
10%–15% lower than in HCV monoinfection. The treatment of 
HCV is often recommended prior to highly active antiretroviral 
therapy (HAART) to avoid the issues of drug interactions on 
HCV therapy and the risk of HAART-related hepatotoxicity. 
Many vertically HIV-infected children however are started 
on HAART therapy very early on when HCV therapy is not 
available below the age of three years.68 The treatment in young 
infants coinfected with HIV and HCV should be focused on 
HAART therapy first since they may spontaneously clear 
HCV by age 2–3 years and IFN α therapy could potentially 
cause neurologic side effects. It is also possible that combina-
tion therapy should be considered in younger children with 
CHC aged between 2–3 years, particularly in those with high 
HCV viral load. New therapies, including HCV PIs, Nis, and 
NNIs are in development and may give therapeutic options 
for HIV-HCV-coinfected children in the future.66
Liver transplantation in children 
with CHC
The outcomes of OLT are not favorable in adult patients 
with CHC.69,70 Data from the United States was based on 
retrospective assessment of all pediatric patients below the 
age of 17 years who have undergone liver transplant for 
management of HCV infection using the United Network 
for Organ Sharing OLT database.71 The patient and graft 
survival rates at five years after OLT in these young subjects Therapeutics and Clinical Risk Management 2009:5 657
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were 71.6% and 55%, respectively, comparable to reported 
rates in adult patients. Rates were considerably lower after 
re-transplantation (55.5% and 33.8%, respectively) with 34% 
dying following initial transplantation or re-transplantation. 
More studies and observation are required to weigh risks and 
benefit of liver transplant and criteria for medical treatment 
of HCV in children with end-stage liver disease.
Cost and financial burden
The financial burden of HCV is undoubtedly high in both 
developed and developing countries, with projected medi-
cal costs of $10.7 billion in adults from 2010 to 2019 and 
approximately $426 million for the next 10 years.72–74 
Jhaveri and colleagues have recently estimated the direct 
medical costs related to HCV in childhood projected for the 
next decade. These include US$26 million for screening, 
$117–206 million for monitoring, and $56–104 million for 
treatment costs.72 The knowledge on global, regional, and 
national rates of morbidity and mortality associated with 
HCV infection based on prevalence, incidence, transmis-
sion and economics in each part of the world as well as a 
better understanding of the natural history of HCV infection 
are required in estimating the global burden of the disease 
associated with HCV infection in children.
Prevention
Currently, there is no effective way to prevent the transmis-
sion of HCV from mother to infant. It is not certain when 
during pregnancy and delivery HCV transmission occurs, 
however, one study suggested that 1/3 to 1/2 of infants 
acquiring HCV from their mothers were infected in utero.75 
Although HCV RNA is detectable in maternal colostrum, 
viral transmission via breastfeeding has not been well 
documented. Inactivation of the virus by gastric acid and 
very low levels of virus in breast milk may explain this 
potential protective mechanism. The American Academy 
of Pediatrics and the American College of Obstetricians and 
Gynecologists support breastfeeding by mothers with HCV 
infection.76 At present neither elective Cesarean section 
nor avoidance of breastfeeding should be recommended to 
HCV-infected women77 although scattered reports do show a 
higher risk of HCV transmission for infants whose mothers 
were HCV-RNA positive in breast milk.78 However, Mast 
and colleagues reported that membrane rupture 6 hours and 
internal fetal monitoring were associated with increased rates 
of transmission of HCV from mother to infant, suggesting a 
possibility of reduction of transmission by modification of 
obstetric practices.79 An association of higher transmission 
rates with intrapartum exposure to virus-contaminated 
maternal blood was reported secondary to a perineal or vagi-
nal laceration.80 There is definitely a role for public education 
about risk avoidance for high risk children and adolescents. 
Schwarz and colleagues recently reported that 19% of home-
less caregivers were anti-HCV positive and no cases of 
HCV infection were found in their children, suggesting the 
importance of directing preventive education to the young.80 
Unlike HIV infection, antiviral therapy is contraindicated in 
pregnant women and not available in young infants with HCV 
infection. Preventing maternal to fetal transmission in HCV 
infection is a very important research goal and will require 
a multidisciplinary approach.
Vaccines
HCV vaccines have been developed using structural protein 
E1 and E2, DNA, and viral vectors with the purpose of 
stimulating both a humoral and a cellular response.81 
Development of an effective HCV vaccine has long been 
defined as a difficult challenge due to the considerable 
variability of this RNA virus.81 Convalescent humans and 
chimpanzees could be re-infected after re-exposure. Targets 
at E2 with hypervariable regions constantly change with an 
evolving quasispecies profile.81 A phase I study of vaccine 
using protein E1 resulted in a humoral and cellular response 
in healthy subjects.82 The induction and maintenance of 
strong helper and cytotoxic T-cell immune responses against 
multiple viral epitopes are necessary for viral protection as 
seen in chronic infection of chimpanzees receiving prophy-
lactic vaccines. Cellular responses may be enhanced by rapid 
induction of cross-neutralizing antibodies via a multispecific 
B-cell response. CHC carriers are known to have impaired 
immune function and restoring T-cell functions is expected 
to enhance the efficacy of therapeutic vaccine in current and 
future clinical trials.83
Conclusion
CHC has become a global health concern and will leads to 
increasingly financial burden. Maternal to fetal transmis-
sion becomes the most common route of HCV acquisition 
in pediatric population. The majority of these children with 
CHC do well, but their liver disease course could eventually 
transform into chronic liver disease and its complication 
in early adulthood given the lengthy duration of HCV 
infection since birth. Standard combination therapy with 
pegIFN and RBV seems to be promising in the pediatric 
population. PegIFN, despite all its side effects, will remain 
the key element of HCV treatment. RBV is essential as a Therapeutics and Clinical Risk Management 2009:5 658
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combination therapy with pegIFN and may be replaced 
when safer or more potent drugs are available. A shorter, 
safer, and more effective therapy or probably a combination 
of other potent antiviral agents preventing the development 
of resistant viral strains is the future ideal therapy for HCV 
infection for both children and adults. Although there is 
the hope of spontaneous viral clearance in children aged 
less than 3 years, the majority of HCV-infected children 
will have CHC. With that regard, the use of combination 
therapy of pegIFN/RBV in young children with HCV needs 
urgent evaluation along with a critical review of the adverse 
side effects, risks/benefit ratio of the therapy, and socio-
economic and ethical considerations. A better response to 
HAART therapy among vertically HIV-infected infants 
who begin immediate treatment in recent studies or prenatal 
therapy in pregnant HIV-infected mothers should be a good 
model for study of treatment of vertically HCV-infected 
children.
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